
• Better Clinical Outcomes
• Improving Patient Satisfaction

www.cardivamedical.com
Safe

RAPID HEMOSTASIS FOR INTERVENTIONAL AND DIAGNOSTIC PROCEDURES

RESPECT – Level 1 Evidence: Prospective, Multi-Center Randomized Clinical Trial

**Percent Complication Rates**

<table>
<thead>
<tr>
<th>Device</th>
<th>% Major Complications</th>
<th>% Minor Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manual Compression</td>
<td>0.2%</td>
<td>4.6%</td>
</tr>
<tr>
<td>AngioSeal</td>
<td>1.3%</td>
<td>2.3%</td>
</tr>
<tr>
<td>PerClose</td>
<td>0.9%</td>
<td>1.8%</td>
</tr>
<tr>
<td>StarClose</td>
<td>0.6%</td>
<td>3.4%</td>
</tr>
<tr>
<td>Mynx</td>
<td>0.5%</td>
<td>3.7%</td>
</tr>
<tr>
<td>ExoSeal</td>
<td></td>
<td>9.0%</td>
</tr>
<tr>
<td>VASCADE</td>
<td>1.1%</td>
<td></td>
</tr>
</tbody>
</table>

** Data for the chart is from U.S. FDA SSED and IFU's and includes both Interventional and Diagnostic treatment arms. All ITT patients and events are included in the chart.

TIME TO HEMOSTASIS

P < 0.0001

VASCADE: 4.8 Minutes
Manual Compression: 21.4 Minutes

TIME TO AMBULATION

P < 0.0001

VASCADE: 3.8 Hours
Manual Compression: 5.8 Hours

Interventional and Diagnostic Cases

1. IFU’s and / or SSED’s of commercially available leading brands (VASCADE, AngioSeal, Mynx, Perclose, Starclose, Exoseal).

ELEGANTLY SIMPLE, MECHANICAL AND PHYSIOLOGICAL HEMOSTASIS

Exchange sheath for VASCADE and verify disc location
Release collagen patch
Remove VASCADE and obtain hemostasis

2 mechanisms of action
mechanical and physiological

~13X expansion of collagen patch

BIOABSORBABLE collagen

RAPID HEMOSTASIS
in heparinized blood

>½ MILLION discs sold

SIMPLE design

utilizes existing PROCEDURAL SHEATH

EXTRAVASCULAR

3. Includes all Cardiva Medical products sold as of May 2017
4. Data on file at Cardiva Medical
Guaranteed

SHARING RISK BY SHARING COSTS

In Performance Guarantee Accounts:

- Offsets your costs of complications
- <1 in 1,000 complications
- Easy to implement


ORDERING INFORMATION:

<table>
<thead>
<tr>
<th>Product</th>
<th>Model Number</th>
<th>Description</th>
<th>Order Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>VASCADE 5F VCS</td>
<td>700-500DX-05U</td>
<td>5 French</td>
<td>1 Box (5 Devices/Box)</td>
</tr>
<tr>
<td>VASCADE 6/7F VCS</td>
<td>700-580I-05U</td>
<td>6/7 French</td>
<td>1 Box (5 Devices/Box)</td>
</tr>
</tbody>
</table>

The VASCADE® Vascular Closure System (VCS) is indicated for femoral arterial or femoral venous access site closure while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures using a 5F, 6F, or 7F procedural sheath.

The VASCADE VCS is also indicated to reduce time to discharge eligibility when used for femoral arterial closure in patients who have undergone diagnostic endovascular procedures using a 5F, 6F, or 7F procedural sheath.

CONTRAINDICATIONS: The VASCADE VCS should not be used in patients with a known allergy to bovine derivatives.

Before use, physicians should review all risk information, which can be found in the “Instructions for Use.”

Founded in July 2002, CARDIVA Medical, Inc. is a privately held medical device company that is focused on developing and commercializing innovative vascular closure technologies designed to help the body heal itself.

1615 Wyatt Drive, Santa Clara, CA 95054
P: 866.602.6099 F: 866.602.1795
customerservice@cardivamedical.com
www.CardivaMedical.com

2019© Cardiva Medical, Inc.
VASCADE is a registered trademark of Cardiva Medical, Inc.
LIT 3575 Rev D